Group 1 - The 19th China (Shenzhen) International Logistics and Supply Chain Expo showcased the Salt Yan Comprehensive Bonded Zone, emphasizing its "Bonded+" ecosystem and collaborative development capabilities [1][2] - The Salt Yan Comprehensive Bonded Zone was awarded the title of "Excellent Logistics Demonstration Park" during the event, highlighting its strong logistics service capabilities and industrial development achievements [1] - The exhibition featured diverse industries, including bonded maintenance, cold chain logistics, cross-border e-commerce, and international supply chains, attracting numerous business interactions and cooperation intentions [1][2] Group 2 - The "Innovation Integration · Ecological Win-Win: 8th Logistics and Supply Chain Collaborative Development Conference" was successfully held, where the Salt Yan Economic Development Service Center presented the industrial functions and business environment of the Salt Yan District and Comprehensive Bonded Zone [2] - The "Bonded+" ecosystem was promoted, detailing the full chain of policy benefits and flexible functions that support the development of the supply chain service industry [2] - Salt Yan District is positioned as a key hub for high-quality economic development, housing 275 enterprises across modern logistics and international trade, and is recognized as a core hub for cold chain logistics in Shenzhen [3]

Group 1 - Guangdong has achieved the top position in regional innovation capability in China for the ninth consecutive year, according to the "China Regional Innovation Capability Evaluation Report 2025" [1] - The report evaluates regional innovation capabilities based on five primary indicators, with Guangdong ranking first in enterprise innovation and innovation environment, and second in innovation performance and knowledge creation [1] - Guangdong's R&D expenditure has surpassed 510 billion yuan, maintaining the highest level in the country, with an R&D intensity of 3.6% [1] Group 2 - The Guangdong-Hong Kong-Macao Greater Bay Area has established multiple major scientific infrastructure projects, including 45 national key laboratories [2] - Guangdong's enterprises have shown strong performance in innovation, ranking first in design capability and technology enhancement, with 77,000 high-tech enterprises contributing significantly to innovation [2] - The "Zhuo Yue" plan has been implemented to strengthen foundational research, allocating over one-third of provincial science and technology innovation funds to basic research [3]

澳门科技大学副校长姜志宏 实验室筑基破局 如今，姜志宏身兼澳门科技大学分管科研副校长、中药机制与质量全国重点实验室主任。他说："我们 始终以'国家所需、澳门所长'为原则，承担中药现代化的开路先锋角色，目前聚焦6大研究方向——中 药tRNA来源小核酸新药研发、中药暗物质质量控制技术、tRNA表观遗传抗肺纤维化新药、航天育种人 参评价、离子通道创新药，以及新药与保健产品转化研究。" 十余年间，姜志宏带领团队交出了亮眼答卷：发表SCI论文1600多篇，获授权专利68项，更有多项成果 打破"科研与产业脱节"的壁垒。"我们最看重成果转化，要让研究真正服务民生。"姜志宏举例，与广药 集团合作研发的白云山复方板蓝根颗粒，成了澳门药监局挂牌后首个口服创新型同名同方新药；三项小 核酸专利转让，创下澳门高校科研成果转化金额最高纪录，还拿下澳门首个生物医学领域技术发明一等 奖；从红树林植物中提取的甾体化合物，作为抗黑色素瘤新药，2021年已获国家药监局I、II期临床批 文。 深澳携手谋创新 深圳商报记者 刘娥 文/图 "深澳在生物医药领域的合作，不是'选择题'，而是'必答题'——两地优势互补，才能在分子药物创新赛 道上跑出加速度。 ...

Core Insights - The 92nd China International Medical Equipment Fair (CMEF) showcases nearly 3,000 companies from around 20 countries, with an exhibition area of approximately 160,000 square meters and over 100,000 expected professional visitors [1][3] Group 1: Innovation and Technology - The event highlights innovative medical technologies, including high-frequency surgical devices and AI health care platforms, demonstrating how technology integrates into healthcare and elder care [2][4] - Guangdong Baisheng Medical Equipment Co., Ltd. presents a range of products, including high-frequency surgical devices and minimally invasive surgical instruments, showcasing the latest advancements in medical technology [2] - AI-driven products, such as the "AI Physiotherapy Robot," are gaining attention for their ability to provide personalized rehabilitation plans, reflecting the growing trend of AI integration in healthcare [2][4] Group 2: Industry Trends - The fair features 28 thematic exhibition areas focusing on trends such as smart technology applications, domestic core component production, international cooperation, and comprehensive health management [4] - Emerging technologies like brain-computer interfaces, AI integration, and medical robotics are prominently displayed, indicating a shift in the medical device industry towards intelligent solutions [4] Group 3: Global Participation - The event attracts exhibitors from various regions in China, including Guangdong, Jiangsu, and Zhejiang, as well as international exhibitors from countries like Germany, the USA, and Japan, emphasizing its global significance [3][5] - The fair serves as a platform for both industry giants and small enterprises to showcase their innovations, enhancing visibility and market penetration for participating companies [5]

湾区跨境联盟以"整合全链资源，赋能湾区电商"为核心使命，将"卖家、服务商、制造商、平台、资 本"全链路资源整合，构建开放、协同、共赢的生态体系，全面提升区域内企业的国际竞争力。 2025湾区跨境出海新生态大会在深举行 【深圳商报讯】（首席记者 刘琼）9月26日，2025湾区跨境出海新生态大会在深圳举行。本次大会 以"聚势启航·链通全球"为主题，约300位全球主流电商平台、商协会、投资机构、湾区制造商和跨境电 商卖家代表参会。会上，湾区跨境联盟正式发起成立，大湾区跨境电商产业协同进入新的发展阶段。 活动当天，大会设置3场专业圆桌交流，汇聚20余位行业大咖，围绕AI应用、平台布局、资本趋势三大 核心议题展开深度研讨，为跨境电商企业出海提供精准指引。 在"穿越周期：以AI驱动决策与效率突围2025"的主题圆桌中，与会者深入探讨了人工智能如何成为企业 穿越经济周期的核心工具。行业人士指出，在流量获取、营销内容生成及数据分析层面，AI技术正带 来颠覆性变革，尤其在TikTok等新兴平台效果显著。同时，AI更深层次的价值在于驱动商业决策智能 化，优化供应链管理，提升全链条运营效率，助力企业在红海竞争中构建差异化优势。 面 ...

目前，合合信息股东东方富海持有公司709.47万股，占公司总股本的5.07%，东方富海二号持有公司333.87万股，占公司总股本的2.38%。 据悉，东方富海与东方富海二号系由同一执行事务合伙人东方富海（芜湖）股权投资基金管理企业（有限合伙）管理的私募基金，合计持有公司7.45%的 股份，股份来源为公司首次公开发行前取得的股份及资本公积转增股本取得的股份，上述股份已于2025年9月26日起上市流通。 | 股东名称 | 东方富海、东方富海二号 | | --- | --- | | 计划减持数量 | 不超过:4,200,000 股 | | 计划减持比例 | 不超过:3% | | 减持方式及对应减持数 | 集中竞价减持,不超过:4,200,000 股 | | 量 | 大宗交易减持,不超过:4,200,000 股 | | 减持期间 | 2025年10月28日〜2026年1月27日 | | 拟减持股份来源 | IP0 前取得、资本公积转增股本取得 | | 拟减持原因 | 自身资金需求 | 根据市场公开信息整理，合合信息9月26日有6867.02万股限售股份解禁，为公司首发原股东限售股份，首发战略配售股份，占公司总股本49 ...

Core Viewpoint - Beijing Anshi Biotechnology Co., Ltd. has received acceptance for its IPO application on the Sci-Tech Innovation Board, aiming to raise 2.45 billion yuan [1][2]. Company Overview - The company focuses on innovative anti-tumor drugs to address significant unmet clinical needs and is transitioning into a comprehensive innovative pharmaceutical enterprise [2][3]. - Anshi Biotechnology is currently unprofitable and is listed under the non-profitable standard [2]. Financial Performance - As of the signing date of the prospectus, the company has only one main product, Wanbi Rui (Bertinib), approved for sale in China, which is still in the early commercialization stage [3]. - The company reported a cumulative unabsorbed loss of 782 million yuan as of the end of the reporting period [4]. - Revenue has shown rapid growth, increasing from 12.96 million yuan in 2023 to 71.66 million yuan in 2024, with Q1 2025 revenue at 64.04 million yuan, nearly five times the 2023 total [4]. Research and Development - R&D expenses have been increasing annually, with figures of 145 million yuan, 184 million yuan, 327 million yuan, and 76.65 million yuan over the reporting period [7]. - The R&D expense ratio is significantly higher than the industry average, indicating substantial investment in drug development [7]. Cash Flow and Financial Health - The company has consistently reported negative cash flow from operating activities, relying heavily on external financing [8]. - As of March 2025, the company had a cash balance of 529 million yuan, with 1.95 billion yuan of the IPO proceeds earmarked for new drug development [8]. Goodwill and Risks - The company has a goodwill amounting to 927 million yuan, which constitutes a significant portion of its non-current assets, raising concerns about potential impairment risks [8][9]. - The actual controller, Shi He Peng, holds 23.81% of the voting rights and is subject to a share repurchase obligation if the IPO is not completed within 36 months [9].

Group 1 - The total market capitalization of listed companies in Longhua District has surpassed 2 trillion yuan, with expectations to reach this milestone by late September 2025 [1][2] - Longhua District is home to 40 listed companies, ranking fourth among Shenzhen districts, with over 80% being private enterprises and more than 70% in advanced manufacturing [2] - The district has implemented a three-year action plan to promote the cultivation and service of listed companies, focusing on mergers and acquisitions, fundraising projects, and "A+H" listings [2][3] Group 2 - The district's industrial transformation aims to shift from an "industrial district" to a "strong industrial and manufacturing district," supported by a high-level advanced manufacturing system [1] - The "1+2+3" industrial system includes digital economy leadership, support from new energy and high-end medical devices, and potential new tracks in semiconductors, low-altitude economy, and modern fashion [1][2] - The revenue growth rate for 30 major industrial listed companies in the district is projected to reach 25% in 2024, indicating a strong clustering effect of headquarters, R&D, and manufacturing [2]

据悉，去年，市市场监管局接续推出"深质贷""深质投"质量投融资产品和工具，打造"质量直接融资+质 量间接融资"联动格局，以"小切口"解决中小企业"融资难"、银行"拓客难"和创投资本"服务科技创新 难"等问题。一年来，市市场监管局在全国首创的"深质投"质量创投模式，实行"IPD遴选+NQI赋能"， 助力处于天使轮、A轮融资区间的初创型科技企业解决投融资难题，联合相关部门举办专场路演、早期 项目对接会6场，推出天使轮和A轮融资项目52个，吸引投资机构60家，其中2个项目获得9500万元融 资，另有9个项目获投资机构对接。 在当天的"深质投"人工智能专场路演环节，来自深圳市威视佰科科技有限公司、深圳市天佑卫星应用技 术有限公司等7家企业和创业团队展示了洞视万物的光谱传感方案、危化行业智能巡检机器人、基于力 觉反馈的人机交互系统、国内首个微信小店全域经营交易闭环型Agent、生境科技、秒拍智诊-全自动AI 影像机器人、无创无感多生理信号健康监测体系7个融资项目，吸引了东方富海、达晨财智、松禾资 本、天使母基金等多家投资机构的关注。 为企业提供全生命周期质量技术和金融服务 【深圳商报讯】（记者 李佳佳）日前，深圳市质量 ...

值得注意的是，极飞科技在2024年实现扭亏为盈，当年的经调整净利润为0.72亿元。2025年上半年，极 飞科技的经调整净利润1.34亿元，同比增长50.56%。2022年至2024年，以及今年上半年，极飞科技的毛 利率分别为17.9%、18.9%、31.9%以及34.3%。 根据弗若斯特沙利文的资料，2024年极飞科技以10.7%和17.1%的市占率在世界农业机器人和农业无人 飞机行业分别排名第二。截至2025年6月30日，极飞科技的经销商网络在国内已经覆盖全国超900个县， 基本实现对中国主要农业生产区域的全面覆盖；同时，极飞科技通过分布在近60个国家和地区的经销 商，对美洲、亚洲、欧洲、大洋洲进行覆盖。 【深圳商报讯】（记者 苑伟斌）9月25日，广州极飞科技股份有限公司（以下简称"极飞科技"）正式向 港交所递交招股说明书，拟主板挂牌上市，华泰国际担任独家保荐人。 极飞科技创立于2007年，是一家农业科技公司，致力于用机器人、人工智能和新能源技术赋能农业。招 股书显示，2022年至2024年，极飞科技的营收分别为6.05亿元、6.14亿元和10.66亿元；今年上半年，极 飞科技的营收从2024年同期的7.3 ...